We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts

MedXY Editorial Team•Oct 1, 2025•Clinical Updates
effectivenessHIVmpoxsafetyVaccine

Highlights

  • MVA-BN (modified vaccinia Ankara-Bavarian Nordic) vaccination is safe and well tolerated among at-risk adults, with low rates of severe adverse reactions.
  • Vaccine effectiveness (VE) for one dose is moderate (58–76%) but improves with two doses (82%). Effectiveness is notably reduced in people living with HIV.
  • Breakthrough mpox infections after vaccination are milder compared to those in unvaccinated individuals.
  • Host baseline immunological states may influence vaccine response and need to be considered in vaccination strategies, especially with constrained vaccine supply.

Study Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Immunogenicity and Safety of Pentavalent Meningococcal MenABCWY Vaccine in Adolescents and Young Adults: Integrated Evidence from Late-Phase Clinical TrialsThis review synthesizes phase 2 and 3 trial data demonstrating that the pentavalent MenABCWY vaccine is immunologically non-inferior and well tolerated compared with MenB-fHbp and MenACWY-CRM vaccines, offering a simplified, effective vacciSep 4, 2026Long-term Safety of Oral Orforglipron in Japanese Patients with Type 2 Diabetes (ACHIEVE-J): A Multicenter, Randomized, Open-label, Phase 3 TrialThis phase 3 trial evaluates the 52-week safety of oral orforglipron in Japanese adults with type 2 diabetes, showing an acceptable safety profile when used alongside diet, exercise, and oral antihyperglycemic drugs.Aug 18, 2026Impact of Multidimensional Social Adversity on Mortality and Rehospitalization in People with HIV and Heart FailureThis study explores how various social adversity domains affect mortality and rehospitalization risks in HIV-positive patients with heart failure, underscoring the importance of holistic social assessments for improving outcomes.Jul 2, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Erythrocytosis in Advanced Thyroid Cancer Therapy: Emerging Safety Concerns with Targeted AgentsErythrocytosis is an underreported hematologic side effect of targeted therapies in advanced thyroid cancers, notably RET inhibitors, occurring early and recurrently without impacting survival outcomes but correlating with disease control rJun 28, 2026
Elevated Heart Failure Risk in People With HIV: Insights from the REPRIEVE TrialThe REPRIEVE trial reveals higher heart failure incidence in people with HIV, particularly among women, Black participants in high-income regions, and those with hypertension or obesity. Traditional risk factors, not HIV-specific markers, wApr 30, 2026
Long-term Immunological and Clinical Outcomes of Monkeypox Virus Infection versus MVA-BN Vaccination: A 24-Month Longitudinal Cohort AnalysisThis 24-month Belgian cohort study demonstrates that natural MPXV infection induces more durable and robust immunity than MVA-BN vaccination. While clinical symptoms mostly resolve within a year, persistent scarring remains common, and vaccMar 2, 2026